News

Under the deal, Clinipace will manage a major trial of PT20, a new iron-based phosphate binder, being developed for the treatment of hyperphosphataemia related to chronic kidney disease

Based on the review, the FDA has determined that they cannot approve the new drug application (NDA) in its present form, stating the NDA does have sufficient information

Pyxant is a contract research laboratory specializing in GLP bioanalytical chemistry support for life sciences clients. Under the deal, Pyxant will offer bioanalytical method development, sample analysis and

CTSI’s Catalyst Awards program solicits applications from university scientists who wish to move their translational research beyond the bench and into product development. The collaboration marks the first

Results of the study were recently published in Molecular Cancer Therapeutics. The study, led by Dr Arnon Nagler, director of the Hematology Division and Bone Marrow Transplantation Center

The product will be produced by Axxess Pharma’s wholly-owned subsidiary, AllStar Health Brands. Axxess Pharma president Dr Daniel Bagi noted the addition of Muscle Explosion expands the potential

The patent that issues will broadly and specifically cover the company’s drug candidates, their pharmaceutical compositions, and their use for treating a number of important gastrointestinal conditions in

Sprout will resubmit the New Drug Application (NDA) for flibanserin, a once-daily treatment for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, by the third quarter. The FDA

In connection with the filing, Arena will receive a milestone payment of $500,000 from Eisai. Arena Pharmaceuticals president and CEO Jack Lief noted with over half of adults